Literature DB >> 21508910

Prevalence and incidence of scoliosis in Turner syndrome: a study in 49 girls followed-up for 4 years.

S Ricotti1, L Petrucci, G Carenzio, C Klersy, V Calcaterra, D Larizza, E Dalla Toffola.   

Abstract

BACKGROUND: Turner syndrome (TS) is a sex chromosome abnormality in females characterized by gonadal dysgenesis, short stature and skeletal malformations like kyphosis and scoliosis. AIM: To evaluate the prevalence of scoliosis and its incidence over 4 year follow-up.
DESIGN: Consists in two parts: cross sectional study and longitudinal study.
SETTING: Outpatient. POPULATION: Forty-nine TS assessed at the Pediatric Outpatients Clinic.
METHODS: Clinical and radiological evaluation of spine.
RESULTS: Cross sectional study: at baseline an high prevalence of minor scoliosis was observed (59%, 95% CI 44-73). The prevalence increased with age (trend test P=0.01). Patients with scoliosis were more frequently on GH therapy (69% vs. 35%, P=0.023). At multivariable analysis (including age, height and GH therapy), height was the only independent correlate of scoliosis. Longitudinal study: of the 20 cases without scoliosis at baseline, 9 were diagnosed with new scoliosis (classified as minor ) after 4 years (incidence of 45% , 95% CI 23-68). We didn't found any predictor of new scoliosis; patients who developed scoliosis 4 years later were older and taller at baseline.
CONCLUSION: TS have a higher risk to develop scoliosis and the age at risk is protracted further with respect to normal subjects. This risk appears influenced by the height of the patient and, indirectly, by the GH therapy. Clinical rehabilitation impact. In TS is necessary a prolonged time of observation (until age twenty) for identifying scoliosis and beginning a rehabilitation program.

Entities:  

Mesh:

Year:  2011        PMID: 21508910

Source DB:  PubMed          Journal:  Eur J Phys Rehabil Med        ISSN: 1973-9087            Impact factor:   2.874


  6 in total

1.  Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets.

Authors:  Nadine Meyerhoff; Dieter Haffner; Hagen Staude; Elke Wühl; Michaela Marx; Rolf Beetz; Uwe Querfeld; Martin Holder; Heiko Billing; Wolfgang Rabl; Carmen Schröder; Olaf Hiort; Jürgen H Brämswig; Annette Richter-Unruh; Dirk Schnabel; Miroslav Živičnjak
Journal:  Pediatr Nephrol       Date:  2017-10-20       Impact factor: 3.714

2.  Influence of growth hormone treatment on radiographic indices of the spine: propensity-matched analysis.

Authors:  Yeo-Hon Yun; Soon-Sun Kwon; Youngdo Koh; Dong-Jun Kim; Jonghyun Ahn; Seung Yeol Lee
Journal:  J Orthop Surg Res       Date:  2017-09-06       Impact factor: 2.359

3.  Associated clinical abnormalities among patients with Turner syndrome.

Authors:  Suna Kilinc; Metin Yildiz; Ayla Guven
Journal:  North Clin Istanb       Date:  2020-04-14

4.  A novel de novo partial xq duplication in a girl with short stature, nonverbal learning disability and diminished ovarian reserve - effect of growth hormone treatment and fertility preservation strategies: a case report and up-to-date review.

Authors:  Francesca Parissone; Mairi Pucci; Emanuela Meneghelli; Orsetta Zuffardi; Rossana Di Paola; Stefano Zaffagnini; Massimo Franchi; Elisabetta Santangelo; Gaetano Cantalupo; Paolo Cavarzere; Franco Antoniazzi; Giorgio Piacentini; Rossella Gaudino
Journal:  Int J Pediatr Endocrinol       Date:  2020-01-09

Review 5.  Inside the Noonan "universe": Literature review on growth, GH/IGF axis and rhGH treatment: Facts and concerns.

Authors:  Stefano Stagi; Vittorio Ferrari; Marta Ferrari; Manuela Priolo; Marco Tartaglia
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-18       Impact factor: 6.055

6.  Safety and Effectiveness of Recombinant Human Growth Hormone in Children with Turner Syndrome: Data from the PATRO Children Study.

Authors:  Philippe Backeljauw; Shankar Kanumakala; Sandro Loche; Karl Otfried Schwab; Roland Werner Pfäffle; Charlotte Höybye; Elena Lundberg; Tadej Battelino; Berit Kriström; Tomasz Giemza; Hichem Zouater
Journal:  Horm Res Paediatr       Date:  2021-07-07       Impact factor: 2.852

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.